Top Stories
Top Stories
Market Insider

Chemours, DuPont shares plummet after testicular cancer liability case

A file photo of testicular cancer as shown in a micrograph.
Steve Gschmeissner | Getty Images

Shares of Chemours and DuPont fell sharply in afternoon trade Wednesday after the Dow component was found liable for a man's testicular cancer in a test case involving 3,500 lawsuits.

According to two sources familiar with the matter, the jury awarded the man $5.1 million. DuPont was found liable, but Chemours — a DuPont spinoff — will bear the cost.

Chemours traded about 22 percent lower, while DuPont fell 1.8 percent.

Chemours said it will appeal the verdict, adding that it retains defenses to claims that DuPont is entitled to indemnification from the judgment, according to Reuters. Chemours' shares ticked higher after hours.

Neither DuPont nor Chemours responded to CNBC's request for comment.